Date: 2015-04-23
Type of information: Nomination
Compound:
Company: Keryx Biopharmaceuticals (USA - NY)
Therapeutic area: Renal diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 23, 2015, Keryx Biopharmaceuticals announced the appointment of John F. Neylan, MD to the newly created position of Chief Medical Officer. In this role, Dr. Neylan will be responsible for oversight of medical affairs, clinical development and pharmacovigilence at Keryx. Dr. Neylan is an accomplished nephrologist, transplantation specialist, and biopharmaceutical executive with broad-based experience in therapeutic development, from the preclinical phase to post-marketing development of therapies across primary care, specialty and rare disease indications. Dr. Neylan comes to Keryx from Genzyme Corporation, where since 2008 he served in the capacity of Senior Vice President, Clinical Development, focusing on specialty metabolic diseases. From 2000-2008, Dr. Neylan served as Vice President, Research and Development for Wyeth Research, overseeing the clinical development of transplantation therapeutics and providing medical affairs support to the transplant franchise. Prior to joining industry, Dr. Neylan held prestigious positions in academia, including Professor of Medicine at Emory University and Assistant Professor of Medicine at UC Davis, serving at both institutions as Medical Director of the respective Renal Transplant Programs, with oversight of the clinical research programs. Dr. Neylan received his BS from Duke University and his MD from Rush Medical School in Chicago. He completed his Internal Medicine residency at Vanderbilt University and fellowships in Nephrology and in Transplantation and Immunogenetics at Brigham and Women\'s Hospital, Harvard University. Dr. Neylan has a proven track record for successful INDs, NDA/BLAs, and MAAs involving NCEs, polymers, biologics and RNA-based therapeutics and has authored more than 70 scientific manuscripts and book chapters. He is Past-President of the American Society of Transplantation and past Board Member of the National Kidney Foundation, and a past Industry Representative on the FDA Cardiovascular and Renal Drugs Advisory Committee.
Financial terms:
Latest news:
